| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 20.08. | Cardio Diagnostics Holdings, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.08. | Cardio Diagnostics launches CLIA-certified laboratory in Iowa | 2 | Investing.com | ||
| 07.08. | Cardio Diagnostics Holdings, Inc. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 29.07. | Sika hebt IT auf C-Level und holt Jochen Werling als CDIO | 47 | CIO | ||
| 02.07. | Die drei Transformationen des Etex-CDIO Dirk Altgassen | 2 | CIO | ||
| CARDIO DIAGNOSTICS Aktie jetzt für 0€ handeln | |||||
| 28.04. | UK.gov's DCMS to new CDIO: migrate from Google to Microsoft, overhaul ERP, build a team | 4 | The Register |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MODERNA | 150,76 | +12,51 % | Moderna und BioNTech lassen Corona endgültig hinter sich | Aus dem alten Duell der beiden Corona-Gewinner ist ein neuer Wettbewerb geworden. Moderna erlebt nach überzeugenden Phase-3-Daten für eine personalisierte Krebstherapie eine spektakuläre Neubewertung.... ► Artikel lesen | |
| IMMUNITYBIO | 7,330 | -0,95 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| TRINITY BIOTECH | 7,350 | +1,66 % | Trinity Biotech plc: Trinity Biotech Provides Diagnostics Business, Transformation And Corporate Update | - Continued execution of transformation strategy drives commercial, manufacturing and pipeline progress - PrePsia patent portfolio expands to nine granted U.S. and European patents - Company issues... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,880 | -2,04 % | Rocket Pharma upgraded at Needham as FDA OKs pivotal trial design | ||
| TANGO THERAPEUTICS | 22,270 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,990 | +1,62 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| ONCONETIX | 0,652 | -0,70 % | Onconetix, Inc.: CORRECTED: Onconetix Provides Strategic Bridge Financing to Realbotix LLC in Support of Pending Acquisition | Initial Advance of $2.5 Million to Realbotix LLC to Support Growth and Working Capital; Non-Interest Bearing Facility Is Automatically Cancelled and Discharged in Full Upon Closing of Pending Acquisition... ► Artikel lesen | |
| CG ONCOLOGY | 78,25 | +4,86 % | CG Oncology auf Morgan Stanley Konferenz: Pläne für Markteinführung, Daten und Skalierung | ||
| QIAGEN | 38,695 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,975 | 0,00 % | Tempus verlängert Datenpartnerschaft mit Recursion bis 2029 | ||
| NURIX THERAPEUTICS | 25,410 | -0,12 % | Nurix auf Morgan Stanley Healthcare-Konferenz: Roche-Deal als Wachstumstreiber | ||
| ARRIVENT BIOPHARMA | 29,740 | +2,91 % | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2026 Financial Results | Topline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to... ► Artikel lesen | |
| OBSIDIAN THERAPEUTICS | 17,330 | -2,37 % | Obsidian Therapeutics Completes Closing of Transaction with Galera Therapeutics and Previously Announced Private Placement of $350 Million | • Obsidian Therapeutics to focus on the advancement of its pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors
• Post-transaction cash and cash equivalents... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 299,10 | -0,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| BEAM THERAPEUTICS | 25,260 | +1,28 % | Beam Therapeutics Presents Updated Clinical Data from the Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at the European Respiratory Society (ERS) Congress 2026 | BEAM-302 Continues to Demonstrate Potential as One-time Treatment for Both Lung and Liver Manifestations of AATD, with AAT Protein Production Under Normal Physiological Control With Up to 18 Months... ► Artikel lesen |